Extended Data Fig. 4: Binding of anti-SARS-CoV-2 monoclonal antibodies to Vero cells infected with Delta and Omicron variants.

Vero cells were infected with the indicated variants at an MOI of 0.01. After 48 h, cells were stained with 1 or 0.1 μg ml⁻¹ of the indicated anti-SARS-CoV-2 monoclonal antibodies (Bamlanivimab, Etesevimab, Casirivimab, Imdevimab, Adintrevimab, Cilgavimab, Tixagevimab, Regdanvimab, Sotrovimab) and analysed by flow-cytometry. a. Gating strategy and example of gates on negative (non-infected) or positive (Delta-infected) samples. b. The anti-S2 pan-coronavirus mAb 10 was used to measure the percentage of infected cells. Histograms show binding of mAb 10 to Vero cells infected with the indicated variants. c. Radar charts represent for each antibody the logarithm of the median fluorescent intensity (MFI) of the staining. Data are representative of two or three independent experiments. d. Inhibitory Concentrations 50% (IC50) of mAbs against Delta and Omicron variants. The IC50 of the indicated mAbs and some of their combinations were calculated from the neutralization curves displayed in Fig. 1b. Results are in ng ml⁻¹. Colour code: Grey: inactive mAbs. Green: mAbs displaying a neutralizing activity. The binding activity was measured by flow cytometry on Vero cells infected with the indicated variants. Results are presented as the fold-decrease of binding to Omicron-infected cells relative to Delta-infected cells.

Source data